Manufacturer record

Revantis Healthcare: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

3 batches manufactured by Revantis Healthcare (Himachal Pradesh) were declared Not of Standard Quality between February 2025 and July 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

3 records linked to Revantis Healthcare in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
3Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Feb 2025 to Jul 2025

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

3
NSQ batches since 2025
3
Products affected
Description
Most common failure
Jul 2025
Latest alert

Flagged batches per year

2025 · 3

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
ZONAC-P TAB Tablets, Aceclofenac & Paracetamol Tab RHT25-021Mfg 2025-01 · Exp 2026-12 The label should be mentioned as ACECLOFENAC AND PARACETAMOL IP. But the letters IP not mentioned after the product name ACECLOFENAC AND PARACETAMOL.Labelling State Lab, Drugs Control Laboratory, TelanganaState lab Jul 2025
Telmisartan & Amlodipine TabletsIP (Lanztel-AM) RHT24-402Mfg 2024-07 · Exp 2026-06 Does not comply with respect to test for AssayAssay State lab , PuducherryState lab May 2025
TELMISARTAN & HYDROCHLORO THIAZIDE TABLETS IP (Lanztel-H) RHT24- 401Mfg ? · Exp ? For the received sample Telmisartan & Hydrochlorothiazide Tablets IP, Presence of Spot and Rough Surface was observed which should not be present as per Drugs & Cosmetics (Amendment) Act, 2008 of DCC Guidelines on Not Of Standard Quality (NSQ) Drugs Approved in 1993 (Annexure A) Tablets vide serial No. (i) Presence of Spot/discoloration (vii) Rough surface and rule 124B of the Drugs Rules,1945. -NSQDescription PuducherryState lab Feb 2025

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.